We are currently in our Series A round of funding. Click here to view our investor materials.
- ENB to present at 2016 Pitch Fest organized by New York Bio
- ENB CSO and Co-founder Dr. Sumayah Jamal wins Best-in-show at 1st Pitch Life Science NYC
- ENB Therapeutics accepted for presentation at the 2016 HemOnc Today Melanoma Conference in NYC
- ENB’s Co-founder and CSO Dr. Sumayah Jamal is accepted into the 2016 Pharma Class of Springboard Health Innovation Hub
- ENB Lead Product ENB001 Awarded Orphan Drug Designation by the FDA